In an ovarian cancer model, AXL inhibition results in a DDR response and sensitivity to ATR inhibition, and the AXL binding partner SAM68 shows DNA damage phenotypes upon loss, similar to AXL inhibition. Here, AXL is linked to ovarian carcinoma.